CAMBRIDGE, Mass., June 22, 2026--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced ...
Morning Overview on MSN
A light-and-sound headset for Alzheimer’s is finishing a major late-stage trial this month
Cognito Therapeutics is wrapping up the largest clinical trial ever conducted on a non-drug device for Alzheimer’s disease.
Cognito Therapeutics to Present New Data Highlighting Effects of Spectris™ on Lipid Transport Biomarkers in Alzheimer’s Disease at AAIC 2026 Company to present data demonstrating increases in CSF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results